Madeira Maria H, Marques Inês P, Ferreira Sónia, Tavares Diana, Santos Torcato, Santos Ana Rita, Figueira João, Lobo Conceição, Cunha-Vaz José
AIBILI, Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal.
Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research, University of Coimbra, Coimbra, Portugal.
Front Neurosci. 2021 Dec 21;15:800004. doi: 10.3389/fnins.2021.800004. eCollection 2021.
Diabetic retinopathy (DR) has been considered a microvascular disease, but it has become evident that neurodegeneration also plays a key role in this complex pathology. Indeed, this complexity is reflected in its progression which occurs at different rates in different type 2 diabetic (T2D) individuals. Based on this concept, our group has identified three DR progression phenotypes that might reflect the interindividual differences: phenotype A, characterized by low microaneurysm turnover (MAT <6), phenotype B, low MAT (<6) and increased central retinal thickness (CRT); and phenotype C, with high MAT (≥6). In this study, we evaluated the progression of DR neurodegeneration, considering ganglion cell+inner plexiform layers (GCL+IPL) thinning, in 170 T2D individuals followed for a period of 5 years, to explore associations with disease progression or risk phenotypes. Ophthalmological examinations were performed at baseline, first 6 months, and annually. GCL+IPL average thickness was evaluated by optical coherence tomography (OCT). Microaneurysm turnover (MAT) was evaluated using the RetMarkerDR. ETDRS level and severity progression were assessed in seven-field color fundus photography. In the overall population there was a significant loss in GCL+IPL (-0.147 μm/year), independently of glycated hemoglobin, age, sex, and duration of diabetes. Interestingly, this progressive thinning in GCL + IPL reached higher values in phenotypes B and C (-0.249 and -0.238 μm/year, respectively), whereas phenotype A remained relatively stable. The presence of neurodegeneration in all phenotypes suggests that it is the retinal vascular response to the early neurodegenerative changes that determines the course of the retinopathy in each individual. Therefore, classification of different DR phenotypes appears to offer relevant clarification of DR disease progression and an opportunity for improved management of each T2D individual with DR, thus playing a valuable role for the implementation of personalized medicine in DR.
糖尿病视网膜病变(DR)一直被认为是一种微血管疾病,但显而易见的是,神经退行性变在这种复杂的病理过程中也起着关键作用。事实上,这种复杂性体现在其进展过程中,不同的2型糖尿病(T2D)个体进展速度不同。基于这一概念,我们的研究小组确定了三种DR进展表型,它们可能反映个体间差异:表型A,其特征为微动脉瘤周转率低(MAT<6);表型B,微动脉瘤周转率低(<6)且中心视网膜厚度(CRT)增加;表型C,微动脉瘤周转率高(≥6)。在本研究中,我们评估了170例随访5年的T2D个体中DR神经退行性变的进展情况,以探讨其与疾病进展或风险表型的相关性,其中神经退行性变表现为神经节细胞+内网状层(GCL+IPL)变薄。在基线、最初6个月及之后每年进行眼科检查。通过光学相干断层扫描(OCT)评估GCL+IPL的平均厚度。使用RetMarkerDR评估微动脉瘤周转率(MAT)。通过七视野彩色眼底摄影评估早期糖尿病性视网膜病变研究(ETDRS)水平和严重程度进展。在总体人群中,GCL+IPL有显著变薄(-0.147μm/年),且与糖化血红蛋白、年龄、性别和糖尿病病程无关。有趣的是,GCL+IPL的这种渐进性变薄在表型B和C中更为明显(分别为-0.249和-0.238μm/年),而表型A相对稳定。所有表型中均存在神经退行性变,这表明视网膜血管对早期神经退行性变化的反应决定了每个个体视网膜病变的进程。因此,不同DR表型的分类似乎为DR疾病进展提供了相关的清晰解释,并为改善每个患有DR的T2D个体的管理提供了机会,从而在DR个性化医疗的实施中发挥重要作用。